Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of DCVax-L in newly diagnosed glioblastoma
2011-001977-13Phase 3Unknown
- Sponsor
- Northwest Biotherapeutics
- Start
- Jul 2012
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing DCVax-L randomized arm with Placebo randomized arm (2 arms). Primary endpoint: Overall survival in newly diagnosed glioblastoma. Status: unknown.
02
Drugs
DCVax-L
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2011-001977-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001977-13.